A detailed history of Paradigm Biocapital Advisors LP transactions in Argenx Se stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 480,374 shares of ARGX stock, worth $303 Million. This represents 9.39% of its overall portfolio holdings.

Number of Shares
480,374
Previous 538,139 10.73%
Holding current value
$303 Million
Previous $231 Million 12.58%
% of portfolio
9.39%
Previous 9.37%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $25.1 Million - $31.9 Million
-57,765 Reduced 10.73%
480,374 $261 Million
Q2 2024

Aug 14, 2024

SELL
$356.01 - $451.55 $4.98 Million - $6.31 Million
-13,981 Reduced 2.53%
538,139 $231 Million
Q1 2024

May 15, 2024

BUY
$356.95 - $413.29 $46.2 Million - $53.5 Million
129,543 Added 30.66%
552,120 $217 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $54.6 Million - $81.5 Million
161,134 Added 61.63%
422,577 $161 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $44 Million - $65.4 Million
119,184 Added 83.78%
261,443 $129 Million
Q2 2023

Aug 14, 2023

SELL
$360.14 - $422.58 $14 Million - $16.4 Million
-38,913 Reduced 21.48%
142,259 $55.4 Million
Q1 2023

May 15, 2023

BUY
$334.23 - $403.65 $30.6 Million - $37 Million
91,616 Added 102.3%
181,172 $67.5 Million
Q4 2022

Feb 14, 2023

SELL
$342.17 - $402.31 $253,547 - $298,111
-741 Reduced 0.82%
89,556 $33.9 Million
Q3 2022

Nov 14, 2022

BUY
$343.2 - $395.75 $508,279 - $586,105
1,481 Added 1.67%
90,297 $31.9 Million
Q2 2022

Aug 15, 2022

BUY
$269.58 - $378.88 $23.9 Million - $33.7 Million
88,816 New
88,816 $33.7 Million
Q1 2022

May 16, 2022

SELL
$254.45 - $351.06 $10.7 Million - $14.8 Million
-42,050 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$272.01 - $353.03 $11.4 Million - $14.8 Million
42,050 New
42,050 $14.7 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.